TICKERNERD
Menu
SPRYSPRYHealthcare · Biotechnology

SPRY Stock Forecast: ARS Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 7 Aug 2026
$6.16
+10.90% on the day

The 4 Wall Street analysts covering ARS Pharmaceuticals, Inc. hold a median 12-month price target of $27 — +338.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 8 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$611.7M
Ticker Nerd rank
11 / 100
Median analyst target
$27
Analysts covering
4
Total return, dividends reinvested
1W
+20.0%
1M
−24.8%
YTD
−47.2%
1Y
−65.1%
From 52W high
−65.1%
From 52W low
+20.0%
$5
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SPRY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ARS Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Aug 2026
11 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
51
Accruals
48
Revisions
44
Volatility
41
Value
39
Quality
23
Growth
19
Issuance
18
Momentum
6

Size (51): Smaller than most of the companies we track.

Momentum (6): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own ARS Pharmaceuticals, Inc. — and when they’d sell — is the membership.

Wall Street

SPRY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SPRY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25$30$35Oct 25Jan 26Apr 26Jul 26SPRYHigh $32Median $27Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $21Median $27High $32

The green dot is the last close — the median target sits +338.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 June 2026Leerink PartnersMaintainsOutperform$25 → $24
25 June 2026Leerink PartnersMaintainsOutperform—
28 May 2026Cantor FitzgeraldMaintainsOverweight—
4 Sept 2025Roth CapitalInitiatesBuy—
7 Mar 2025ScotiabankInitiatesSector Outperform—
14 Jan 2025Raymond JamesMaintainsStrong Buy—
13 Jan 2025Leerink PartnersMaintainsOutperform—
8 Oct 2024Cantor FitzgeraldReiteratesOverweight—
20 Sept 2024Leerink PartnersMaintainsOutperform—
16 Sept 2024Cantor FitzgeraldReiteratesOverweight—
9 Sept 2024Cantor FitzgeraldReiteratesOverweight—
20 Aug 2024Cantor FitzgeraldInitiatesOverweight—
13 Aug 2024Raymond JamesUpgradeStrong Buy—
25 July 2024Raymond JamesInitiatesOutperform—
11 Mar 2024WedbushReiteratesOutperform—
5 Mar 2024Leerink PartnersUpgradeOutperform—
13 Nov 2023WedbushMaintainsOutperform—
21 Sept 2023WedbushMaintainsOutperform—
20 Sept 2023William BlairDowngradeMarket Perform—
14 Aug 2023WedbushReiteratesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

SPRY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

ARS Pharmaceuticals, Inc. (SPRY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
168.3×

Cheaper than 4% of US stocks

Price / sales
6.2×

Cheaper than 21% of US stocks

Price / book
10.0×

Cheaper than 11% of US stocks

EV / EBITDA
−2.9×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
184.5%

Higher than 96% of US stocks

Earnings growth (YoY)
184.5%

Higher than 90% of US stocks

Gross margin
72.3%

Higher than 85% of US stocks

Operating margin
−265.2%

Higher than 10% of US stocks

Net margin
−200.0%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−136.4%

Higher than 10% of US stocks

Return on assets
−41.1%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SPRY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SPRYARS Pharmaceuticals, Inc.$611.7M
11
ALTAltimmune, Inc.$598.6M
31
NVCTNuvectis Pharma, Inc.$597.4M
71
CBIOCrescent Biopharma, Inc.$622.4M
56
VSTMVerastem, Inc.$592.0M
56
FTHFaeth Therapeutics, Inc.$628.7M
63
CTNMContineum Therapeutics, Inc.$582.9M
63
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SPRY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest SPRY news & analysis

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

Business Wire · 8 Aug 2026negative

SBS Law announced that ARS Pharmaceuticals, Inc. (SPRY) investors have the opportunity to lead a securities fraud lawsuit against the company. The notice invites eligible SPRY investors to participate in the fraud action.

Why it matters — A securities fraud lawsuit against ARS Pharmaceuticals introduces potential legal and financial risk that SPRY watchers would need to monitor.

Kaplan Fox Notifies ARS Pharmaceuticals Inc. (SPRY) Investors of an Upcoming Lead Plaintiff Deadline on October 5, 2026

Newsfile Corp · 7 Aug 2026negative

Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against ARS Pharmaceuticals on behalf of investors who purchased ARS securities between March 9, 2026 and June 24, 2026, with a lead plaintiff deadline of October 5, 2026.

Why it matters — SPRY watchers would care because the company faces a securities class action lawsuit over the specified class period, which could carry legal and financial implications.

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

PRNewsWire · 7 Aug 2026negative

Rosen Law Firm announced a class action lawsuit on behalf of purchasers of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) securities during the Class Period from March 9, 2026 to June 24, 2026. A class action lawsuit has already been filed in connection with the securities fraud allegations.

Why it matters — SPRY watchers would care because the company faces a securities fraud class action covering purchases made during the stated Class Period, which introduces legal and regulatory risk tied to the company's disclosures.

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY

PRNewsWire · 6 Aug 2026negative

SueWallSt is reminding shareholders that a lead plaintiff deadline of October 5, 2026 applies in a securities class action filed against ARS Pharmaceuticals (SPRY). The lawsuit, covering purchases between March 9, 2026 and June 24, 2026, alleges the company built analyst expectations on a July 1, 2026 CVS Caremark formulary coverage timeline that was not disclosed as at risk of slipping to January 2027, a miss that Wall Street called a "negative shock."

Why it matters — SPRY watchers should note that a securities class action has been filed against the company alleging undisclosed risk around a key formulary coverage timeline, with an approaching lead plaintiff deadline.

FAQ

Frequently asked questions about SPRY stock

What is the SPRY stock price forecast for 2026-2027?

The 4 Wall Street analysts covering ARS Pharmaceuticals, Inc. have a median 12-month price target of $27, with estimates ranging from $21 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SPRY stock a buy right now?

Of the 4 analysts covering ARS Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ARS Pharmaceuticals, Inc. 11 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SPRY?

As at 8 Aug 2026, ARS Pharmaceuticals, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (51 of 100).

Will SPRY stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +338.7% from the last close, and Ticker Nerd's factor model ranks ARS Pharmaceuticals, Inc. 11 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SPRY stock forecast for 2030?

No analyst covering ARS Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $32 over the next 12 months.

How has SPRY stock performed over the past year?

ARS Pharmaceuticals, Inc. returned -65.1% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ARS Pharmaceuticals, Inc. do?

Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes.

What is the latest news on SPRY?

The most recent item we track (Business Wire, 8 Aug 2026): "SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law". SBS Law announced that ARS Pharmaceuticals, Inc. (SPRY) investors have the opportunity to lead a securities fraud lawsuit against the company. The notice invites eligible SPRY investors to participate in the fraud action.

Company

About ARS Pharmaceuticals, Inc.

Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes. The company's primary purpose is to advance medical solutions for allergy-related indications, enhancing safety and convenience for patients affected by conditions such as allergic reactions requiring rapid intervention. Notable for its emphasis on creating user-friendly delivery mechanisms, Ars Pharmaceuticals tailors its offerings to both patients and healthcare professionals seeking reliable and effective emergency treatments. By addressing critical needs within the healthcare industry, Ars Pharmaceuticals plays a significant role in expanding options in allergy treatment and management. Its contributions to the medical field underscore its ongoing commitment to transforming therapeutic landscapes and meeting pressing health challenges.

CEO Mr. Donn Casale · 154 employees · United States · https://ars-pharma.com